Savara is an orphan lung disease company.

Clinical Studies

Savara’s primary focus is IMPALA 2, a second Phase 3 clinical study of Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company is also conducting another pivotal Phase 3 study, called AVAIL, that is evaluating AeroVanc for the treatment of MRSA in people living with cystic fibrosis.

Read more

Indications

We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.

Read more

PAP.Info

Visit our PAP portal where patients and doctors can learn more about this disease

Read more

Back to Top
Savara Nasdaq Opening Bell Ceremony - July 23, 2018
×

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

I accept I decline
Privacy Settings Cookie Policy
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

Analytics Nessessary Privacy Policy Cookie Policy
These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site.
Google Analytics
We track anonymized user information to improve our website.
  • _ga
  • _gid
  • _gat
Google Analytics
Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return. With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
  • __utma
  • __utmt
  • __utmb
  • __utmz
  • __utmv
Decline all Services
Accept all Services